Role of SGLT-2 Inhibitors in Treatment of Patients with Type 2 Diabetes and NAFLD

Background: The role of sodium-glucose cotransporters-2 (SGLT-2) inhibitors in treatment of non-alcoholic fatty liver disease (NAFLD) is unclear. Objective: To examine the possible therapeutic role of SGLT-2 inhibitors in patients with type 2 diabetes and NAFLD. Methods: Pubmed search of English literature up to February 17, 2022. Search terms are fatty liver, SGLT-2, sodium-glucose cotransporter-2 inhibitors, diabetes, weight loss, liver biopsy. Randomized studies are reviewed with focus placed on doubleblind, placebo-controlled trials. Meta-analyses and pertinent reviews are also included.